Sandoz completes acquisition of ranibizumab biosimilar
Click Here to Manage Email Alerts
Key takeaways:
- Sandoz has acquired Cimerli, a ranibizumab biosimilar.
- The transaction includes the full Cimerli business for $170 million.
Sandoz has completed the acquisition of Cimerli, a ranibizumab biosimilar, from Coherus BioSciences, according to a press release.
The acquisition includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, and access to proprietary commercial software, for which Sandoz paid $170 million in cash upfront.
Cimerli (ranibizumab-eqrn), which is interchangeable with Lucentis (ranibizumab, Genentech), is indicated for treating retinal diseases that may cause vision loss, and its acquisition contributes to Sandoz’s U.S. ophthalmic platform, the release said.
“Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the U.S. of pioneering patient access to more affordable and much-needed medicines,” Keren Haruvi, president of Sandoz North America, said in the release. “With the addition of Cimerli to our existing ophthalmology franchise, we can now offer even more treatment options for U.S. patients with vision impairment and loss.”
Read more about
Click Here to Manage Email Alerts